vs
Side-by-side financial comparison of First Western Financial Inc (MYFW) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
First Western Financial Inc is the larger business by last-quarter revenue ($27.5M vs $20.4M, roughly 1.4× Sight Sciences, Inc.). Over the past eight quarters, First Western Financial Inc's revenue compounded faster (10.0% CAGR vs 2.9%).
The Western Union Company is an American multinational financial services corporation headquartered in Denver, Colorado.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
MYFW vs SGHT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.5M | $20.4M |
| Net Profit | — | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | — | -18.0% |
| Net Margin | — | -20.4% |
| Revenue YoY | — | 6.9% |
| Net Profit YoY | — | 64.9% |
| EPS (diluted) | $0.63 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.5M | — | ||
| Q4 25 | $26.7M | $20.4M | ||
| Q3 25 | $26.3M | $19.9M | ||
| Q2 25 | $24.2M | $19.6M | ||
| Q1 25 | $24.8M | $17.5M | ||
| Q4 24 | $24.3M | $19.1M | ||
| Q3 24 | $22.5M | $20.2M | ||
| Q2 24 | $22.8M | $21.4M |
| Q1 26 | — | — | ||
| Q4 25 | $3.3M | $-4.2M | ||
| Q3 25 | $3.2M | $-8.2M | ||
| Q2 25 | $2.5M | $-11.9M | ||
| Q1 25 | $4.2M | $-14.2M | ||
| Q4 24 | $2.7M | $-11.8M | ||
| Q3 24 | $2.1M | $-11.1M | ||
| Q2 24 | $1.1M | $-12.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% |
| Q1 26 | — | — | ||
| Q4 25 | 16.6% | -18.0% | ||
| Q3 25 | 15.1% | -39.7% | ||
| Q2 25 | 13.7% | -59.6% | ||
| Q1 25 | 21.6% | -79.2% | ||
| Q4 24 | 16.1% | -62.5% | ||
| Q3 24 | 11.9% | -55.7% | ||
| Q2 24 | 6.2% | -59.2% |
| Q1 26 | — | — | ||
| Q4 25 | 12.9% | -20.4% | ||
| Q3 25 | 12.1% | -41.0% | ||
| Q2 25 | 10.3% | -61.0% | ||
| Q1 25 | 16.9% | -80.8% | ||
| Q4 24 | 11.3% | -62.1% | ||
| Q3 24 | 9.5% | -54.9% | ||
| Q2 24 | 4.7% | -57.7% |
| Q1 26 | $0.63 | — | ||
| Q4 25 | $0.33 | $-0.07 | ||
| Q3 25 | $0.32 | $-0.16 | ||
| Q2 25 | $0.26 | $-0.23 | ||
| Q1 25 | $0.43 | $-0.28 | ||
| Q4 24 | $0.28 | $-0.23 | ||
| Q3 24 | $0.22 | $-0.22 | ||
| Q2 24 | $0.11 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $273.4M | $63.9M |
| Total Assets | $3.2B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $92.0M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | $0 | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M |
| Q1 26 | $273.4M | — | ||
| Q4 25 | $265.6M | $63.9M | ||
| Q3 25 | $261.5M | $64.3M | ||
| Q2 25 | $258.8M | $70.0M | ||
| Q1 25 | $256.6M | $77.6M | ||
| Q4 24 | $252.3M | $87.5M | ||
| Q3 24 | $248.8M | $95.0M | ||
| Q2 24 | $246.9M | $101.6M |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $115.3M | ||
| Q3 25 | $3.2B | $116.3M | ||
| Q2 25 | $3.0B | $122.0M | ||
| Q1 25 | $2.9B | $129.7M | ||
| Q4 24 | $2.9B | $142.8M | ||
| Q3 24 | $2.9B | $143.6M | ||
| Q2 24 | $2.9B | $149.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | 0.00× | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-1.8M | $-1.8M | ||
| Q3 25 | $10.0M | $-8.7M | ||
| Q2 25 | $-9.1M | $-7.5M | ||
| Q1 25 | $8.0M | $-11.6M | ||
| Q4 24 | $606.0K | $-3.5M | ||
| Q3 24 | $18.8M | $362.0K | ||
| Q2 24 | $-11.5M | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-5.8M | $-2.0M | ||
| Q3 25 | $9.0M | $-8.9M | ||
| Q2 25 | $-9.7M | $-7.8M | ||
| Q1 25 | $7.0M | — | ||
| Q4 24 | $-607.0K | $-3.6M | ||
| Q3 24 | $18.6M | $311.0K | ||
| Q2 24 | $-11.9M | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | -21.6% | -9.7% | ||
| Q3 25 | 34.1% | -44.7% | ||
| Q2 25 | -39.9% | -39.6% | ||
| Q1 25 | 28.1% | — | ||
| Q4 24 | -2.5% | -18.9% | ||
| Q3 24 | 82.3% | 1.5% | ||
| Q2 24 | -52.1% | -44.7% |
| Q1 26 | — | — | ||
| Q4 25 | 14.9% | 0.8% | ||
| Q3 25 | 4.1% | 0.9% | ||
| Q2 25 | 2.4% | 1.1% | ||
| Q1 25 | 4.2% | 0.0% | ||
| Q4 24 | 5.0% | 0.7% | ||
| Q3 24 | 1.3% | 0.3% | ||
| Q2 24 | 1.6% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | -0.54× | — | ||
| Q3 25 | 3.15× | — | ||
| Q2 25 | -3.63× | — | ||
| Q1 25 | 1.91× | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | 8.83× | — | ||
| Q2 24 | -10.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MYFW
| Net Interest Income | $20.9M | 76% |
| Noninterest Income | $6.7M | 24% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
